Gerhard Ries

Managing Partner at LifeCare Partners GmbH

Gerhard Ries

Gerhard Ries

Managing Partner at LifeCare Partners GmbH

Overview
Career Highlights

LifeCare Partners GmbH
BioMedPartners AG

RelSci Relationships

197

Number of Boards

22

Birthday

1969

Age

49

Relationships
RelSci Relationships are individuals Gerhard Ries likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at LSP Management Group BV

Relationship likelihood: Strong

Managing Partner at VI Partners AG

Relationship likelihood: Strong

Partner at BioMedPartners AG

Relationship likelihood: Strong

Chief Executive Officer at Immunic AG

Relationship likelihood: Strong

Executive Chairman at Delenex Therapeutics AG

Relationship likelihood: Strong

Chief Executive Officer & Executive Director at Vectura Group Plc

Relationship likelihood: Strong

Partner, Neomed Management at Omega Fund Management LLC

Relationship likelihood: Strong

Director at Alexion Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Rentschler Biotechnologie GmbH

Relationship likelihood: Strong

Managing Director, Omega Funds Managing Partner, Neomed Management at Omega Fund Management LLC

Relationship likelihood: Strong

Paths to Gerhard Ries
Potential Connections via
Relationship Science
You
Gerhard Ries
Managing Partner at LifeCare Partners GmbH
Education
Ph.D Molecular Biology

The University of Basel is the oldest university in Switzerland. Founded upon the initiative of local citizens in 1460, the University of Basel is a modern and attractive center of teaching, learning, and research situated in the heart of Basel. The University of Basel has been self-managed since 1996 whilst remaining under the jurisdiction of the Cantons of Basel-Stadt and Basel-Landschaft. It provides committed individuals from all over the world a strong academic community and an inspiring work environment. It employs nearly 3,500 people, and its annual budget is around CHF 550 million. The University of Basel is a classic university covering almost all fields of study from Ancient Studies to Zoology. The University of Basel is a rather small university in European standards with around 11,000 students, including 2,000 doctoral students (as of 2007). Around 320 professors and 1,300 lecturers provide an excellent education and encourage independent thinking and responsible action. The proportion of female students is 55% - and rising - and one of five students come from abroad. The University of Basel seeks top performance in research, teaching and service. For years, it is among the 100 best universities in the world, and in the German-speaking world it is one of the top ten.

Diploma in Biotechnology
Career History
Managing Partner
2014 - Current
Director
Prior - 2014

Lumavita AG is a specialty biopharmaceutical company dedicated to bring to market innovative anti-infectives for women's health. Based in Basel, Switzerland, Lumavita was recently financed by a syndicate, lead by Atlas Venture, with CHF18 million (EUR11 million). The company has one product under regulatory review in Switzerland and two further projects in clinical development.

Co-Founder
2002 - 2014

BMP is a venture capital investment manager providing private equity and mezzanine financing to healthcare and human life science companies. The firm focuses on startups, young businesses and spinoffs in the biotechnology, emerging pharmaceuticals, medical technology and diagnostics sectors. They invest in Switzerland and neighboring countries.BioMedInvest is a venture capital fund invested in direct equity. BMP actively scouts for investment opportunities through their network of academic contacts. They target businesses with exceptional growth potential which are driven by distinctive technologies or offering services with unique advantages over current treatments. They generally participate in the first round of financing, either as the lead investor or through syndication with private equity firms and private individuals. The firm fosters the growth of their portfolio companies through management consulting and business support services. Their exit strategies include IPO and sale to leading pharmaceutical corporations or to strategic investors.BioMedInvest II LP is a venture capital fund focused on healthcare-related investments. The fund supports early-stage private firms as well as spin-offs active in segments such as emerging pharmaceutical, biotechnology, medical technology, diagnostics or platform technologies. They look for investments primarily in Switzerland, Germany and neighboring Western Europe. The fund typically invests in a range from CHF 1 million to CHF 10 million, as lead or co-lead investor.BioMedCredit is a mezzanine fund providing growth and expansion capital to small- and mid-size innovative businesses in Switzerland offering specialized services which may not have significant scaling-up potential. They focus on firms operating in products, technologies and services, specifically in the fields of biotechnology, emerging pharmaceuticals, analytical services, biomaterials, bioengineering, bioinformatics, down-stream processing, biotechnological platform technologies, chemical products and reagents, contract R&D and manufacturing, diagnostics, drug delivery technologies, lab technologies, automation, cell culture technologies as well as medical technology. The amount invested of the portfolio firms' lifetime ranges from CHF 0.5 million to CHF 5 million.

Boards & Committees
Member, Board of Directors
2016 - Current

Kuros Biosciences Ltd. engages in the development of products for tissue repair and regeneration. Its products include sealants for tissue restore and orthobiologics for bone healing. The company was founded by Didier Cowling and Jason Schense in 2000 and is headquartered in Schlieren, Switzerland.

Member-Supervisory Board
2015 - Current

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.

Member, Board of Directors
Current

Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Gerhard Ries. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Gerhard Ries's profile does not indicate a business or promotional relationship of any kind between RelSci and Gerhard Ries.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/gerhard-ries-3517586
  • https://relationshipscience.com/person/gerhard-ries-3517586